NeuroPace (NPCE) Competitors $17.68 -0.32 (-1.75%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NPCE vs. TNDM, CDRE, EYE, LQDA, AORT, KMTS, BLFS, PLSE, FNA, and MDXGShould you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Tandem Diabetes Care (TNDM), Cadre (CDRE), National Vision (EYE), Liquidia (LQDA), Artivion (AORT), Kestra Medical Technologies (KMTS), BioLife Solutions (BLFS), Pulse Biosciences (PLSE), Paragon 28 (FNA), and MiMedx Group (MDXG). These companies are all part of the "medical equipment" industry. NeuroPace vs. Tandem Diabetes Care Cadre National Vision Liquidia Artivion Kestra Medical Technologies BioLife Solutions Pulse Biosciences Paragon 28 MiMedx Group NeuroPace (NASDAQ:NPCE) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. Does the MarketBeat Community prefer NPCE or TNDM? Tandem Diabetes Care received 557 more outperform votes than NeuroPace when rated by MarketBeat users. However, 62.26% of users gave NeuroPace an outperform vote while only 60.89% of users gave Tandem Diabetes Care an outperform vote. CompanyUnderperformOutperformNeuroPaceOutperform Votes3362.26% Underperform Votes2037.74% Tandem Diabetes CareOutperform Votes59060.89% Underperform Votes37939.11% Do analysts prefer NPCE or TNDM? NeuroPace currently has a consensus price target of $15.00, indicating a potential downside of 15.13%. Tandem Diabetes Care has a consensus price target of $39.81, indicating a potential upside of 76.40%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than NeuroPace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroPace 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Tandem Diabetes Care 0 Sell rating(s) 8 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53 Which has more volatility and risk, NPCE or TNDM? NeuroPace has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Which has preferable valuation & earnings, NPCE or TNDM? NeuroPace has higher earnings, but lower revenue than Tandem Diabetes Care. NeuroPace is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroPace$84.31M6.88-$32.96M-$0.84-21.04Tandem Diabetes Care$982.95M1.53-$222.61M-$2.78-8.12 Is NPCE or TNDM more profitable? Tandem Diabetes Care has a net margin of -14.84% compared to NeuroPace's net margin of -36.74%. Tandem Diabetes Care's return on equity of -44.19% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets NeuroPace-36.74% -205.41% -28.29% Tandem Diabetes Care -14.84%-44.19%-11.99% Does the media favor NPCE or TNDM? In the previous week, NeuroPace had 4 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 13 mentions for NeuroPace and 9 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.65 beat NeuroPace's score of 0.36 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tandem Diabetes Care 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals believe in NPCE or TNDM? 78.8% of NeuroPace shares are held by institutional investors. 22.2% of NeuroPace shares are held by company insiders. Comparatively, 1.9% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryNeuroPace and Tandem Diabetes Care tied by winning 9 of the 18 factors compared between the two stocks. Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NPCE vs. The Competition Export to ExcelMetricNeuroPaceSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$580.41M$4.53B$5.41B$8.53BDividend YieldN/A43.65%5.22%4.11%P/E Ratio-17.7029.8426.7719.96Price / Sales6.8869.39395.44121.37Price / CashN/A51.0838.2534.62Price / Book22.376.316.874.60Net Income-$32.96M$68.16M$3.23B$248.27M7 Day Performance13.30%19.48%5.32%2.28%1 Month Performance67.69%24.33%13.56%16.43%1 Year Performance122.33%22.25%17.86%8.15% NeuroPace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NPCENeuroPace1.4895 of 5 stars$17.68-1.8%$15.00-15.1%+125.4%$580.41M$84.31M-17.70170Gap DownTNDMTandem Diabetes Care4.5577 of 5 stars$23.45+2.0%$39.81+69.8%-50.2%$1.56B$982.95M-12.152,600Positive NewsCDRECadre2.7375 of 5 stars$35.75+1.0%$37.00+3.5%+12.0%$1.45B$559.81M43.072,240Gap UpEYENational Vision2.8017 of 5 stars$18.76+9.3%$17.57-6.3%+24.7%$1.36B$1.85B-93.8014,000Positive NewsAnalyst ForecastHigh Trading VolumeLQDALiquidia3.3913 of 5 stars$15.75+3.2%$27.13+72.2%+27.5%$1.35B$14.00M-9.6650News CoverageAnalyst DowngradeGap UpAORTArtivion1.618 of 5 stars$28.79-0.4%$31.40+9.1%+22.2%$1.23B$390.08M-1,439.351,300KMTSKestra Medical TechnologiesN/A$23.58+4.0%$27.50+16.6%N/A$1.21B$52.64M0.00300Positive NewsGap UpBLFSBioLife Solutions2.4747 of 5 stars$23.89+2.6%$31.17+30.5%+4.5%$1.13B$87.76M-22.54440News CoveragePositive NewsAnalyst DowngradeGap UpPLSEPulse Biosciences0.9005 of 5 stars$16.79-1.6%N/A+99.0%$1.13B$700,000.000.00140Gap UpFNAParagon 28N/A$13.11+0.1%$12.75-2.7%+75.0%$1.10B$256.18M-17.71343,000High Trading VolumeMDXGMiMedx Group3.9997 of 5 stars$7.25+2.8%$12.50+72.4%-10.4%$1.07B$352.38M13.18870Gap Up Related Companies and Tools Related Companies Tandem Diabetes Care Alternatives Cadre Alternatives National Vision Alternatives Liquidia Alternatives Artivion Alternatives Kestra Medical Technologies Alternatives BioLife Solutions Alternatives Pulse Biosciences Alternatives Paragon 28 Alternatives MiMedx Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NPCE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NPCE Stock Free NPCE Stock Alerts